Compare · MGNX vs XBIT
MGNX vs XBIT
Side-by-side comparison of MacroGenics Inc. (MGNX) and XBiotech Inc. (XBIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGNX and XBIT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MGNX is the larger of the two at $125.3M, about 2.4x XBIT ($52.7M).
- MGNX has been more active in the news (13 items in the past 4 weeks vs 7 for XBIT).
- MGNX has more recent analyst coverage (25 ratings vs 0 for XBIT).
- Company
- MacroGenics Inc.
- XBiotech Inc.
- Price
- -
- -
- Market cap
- $125.3M
- $52.7M
- 1M return
- -45.87%
- -
- 1Y return
- +41.37%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2015
- News (4w)
- 13
- 7
- Recent ratings
- 25
- 0
MacroGenics Inc.
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ã CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Latest MGNX
- Amendment: SEC Form SCHEDULE 13G/A filed by MacroGenics Inc.
- MacroGenics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by MacroGenics Inc.
- MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
- MacroGenics to Participate in Upcoming Investor Conferences
- Director Vasconcelles Michael was granted 44,000 stock options and was granted 7,500 restricted stock units (SEC Form 4)
- SEC Form 3 filed by new insider Vasconcelles Michael
- Director Kuriakose Emil was granted 44,000 stock options and was granted 7,500 restricted stock units (SEC Form 4)
- SEC Form 3 filed by new insider Kuriakose Emil
Latest XBIT
- Amendment: SEC Form SCHEDULE 13G/A filed by XBiotech Inc.
- Director Simard John bought $143,409 worth of shares (70,000 units at $2.05), increasing direct ownership by 2% to 4,261,690 units (SEC Form 4)
- SEC Form 10-Q filed by XBiotech Inc.
- SEC Form 4 filed by XBiotech Inc.
- SEC Form 3 filed by XBiotech Inc.
- Director Simard John bought $711,251 worth of shares (368,524 units at $1.93) (SEC Form 4)
- SEC Form 8-K filed by XBiotech Inc.
- XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
- XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
- SEC Form DEF 14A filed by XBiotech Inc.